Suppr超能文献

[西拉普利对心肌梗死后无症状慢性心力衰竭患者运动耐力和神经体液因子的影响]

[Effect of cilazapril on exercise tolerance and neurohumoral factors in patients with asymptomatic chronic heart failure after myocardial infarction].

作者信息

Fujiwara M, Asakuma S, Nakamura T, Nakamura K, Iwasaki T

机构信息

First Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya.

出版信息

J Cardiol. 1995 Nov;26(5):287-92.

PMID:8523261
Abstract

The effects of cilazapril on exercise tolerance and neurohumoral factors were investigated in old myocardial infarction (OMI) patients with asymptomatic heart failure and reduced left ventricular ejection fraction. Cilazapril (0.5 mg) was administered once daily to OMI patients (n = 20) [NYHA class I, sinus rhythm, ejection fraction by radionuclide scanning < 50% (36.8 +/- 9.1%, mean +/- SD)]. Two weeks later, five patients were excluded from the study because of cough or hypotension, and 15 patients received 1.0 mg cilazapril once daily for the next 6 weeks. Exercise tolerance, neurohumoral factors and ejection fraction were measured in OMI patients before and after administration of cilazapril. Seven age-matched healthy adults served as the controls. OMI patients had latent heart failure because their exercise tolerance values and aldosterone levels were lower and alpha-atrial natriuretic polypeptide levels were higher than those in healthy subjects. In OMI patients, 8 weeks after cilazapril administration, exercise duration increased from 545 +/- 59 to 590 +/- 74 sec (p < 0.05), anaerobic threshold from 17.5 +/- 3.2 to 20.1 +/- 2.8 ml/min/kg (p < 0.05), peak-VO2 from 23.5 +/- 4.7 to 27.1 +/- 4.4 ml/min/kg (p < 0.05), plasma renin activity from 1.34 +/- 1.13 to 5.82 +/- 5.47 ng/ml/hr (p < 0.01) and alpha-atrial natriuretic polypeptide decreased from 100.7 +/- 44.3 to 80.5 +/- 28.0 pg/ml (p < 0.05). In patients with asymptomatic left ventricular dysfunction after myocardial infarction, 8 week's cilazapril administration improved exercise tolerance and neurohumoral conditions.

摘要

在患有无症状心力衰竭且左心室射血分数降低的老年心肌梗死(OMI)患者中,研究了西拉普利对运动耐量和神经体液因子的影响。对OMI患者(n = 20)[纽约心脏协会(NYHA)I级,窦性心律,放射性核素扫描射血分数<50%(36.8±9.1%,平均值±标准差)]每日一次给予西拉普利(0.5毫克)。两周后,5名患者因咳嗽或低血压被排除出研究,15名患者在接下来的6周内每日一次接受1.0毫克西拉普利治疗。在给予西拉普利前后,对OMI患者的运动耐量、神经体液因子和射血分数进行了测量。7名年龄匹配的健康成年人作为对照。OMI患者存在潜在心力衰竭,因为他们的运动耐量值和醛固酮水平较低,而α-心房利钠多肽水平高于健康受试者。在OMI患者中,西拉普利给药8周后,运动持续时间从545±59秒增加到590±74秒(p<0.05),无氧阈值从17.5±3.2毫升/分钟/千克增加到20.1±2.8毫升/分钟/千克(p<0.05),峰值摄氧量从23.5±4.7毫升/分钟/千克增加到27.1±4.4毫升/分钟/千克(p<0.05),血浆肾素活性从1.34±1.13纳克/毫升/小时增加到5.82±5.47纳克/毫升/小时(p<0.01),α-心房利钠多肽从100.7±44.3皮克/毫升降至80.5±28.0皮克/毫升(p<0.05)。在心肌梗死后无症状左心室功能障碍的患者中,给予西拉普利8周可改善运动耐量和神经体液状况。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验